Down Syndrome (Trisomy 21)
Overview
Plain-Language Overview
Down Syndrome (Trisomy 21) is a genetic condition caused by having an extra copy of chromosome 21. It primarily affects the brain and body development, leading to intellectual disability and characteristic physical features. People with this condition often have a distinct facial appearance, including a flat face and upward slanting eyes. It also impacts the heart, digestive system, and immune system, increasing the risk of congenital heart defects and infections. Early childhood development and learning are usually slower, and some individuals may have health challenges throughout life. The condition affects multiple body systems and requires ongoing medical care.
Clinical Definition
Down Syndrome (Trisomy 21) is a chromosomal disorder caused by the presence of a full or partial extra copy of chromosome 21, resulting in trisomy 21. This leads to overexpression of genes on chromosome 21, disrupting normal development and causing intellectual disability, characteristic craniofacial features, and multiple congenital anomalies. The most common cause is nondisjunction during meiosis, leading to a gamete with an extra chromosome 21. Major clinical features include hypotonia, epicanthal folds, single palmar crease, and congenital heart defects such as atrioventricular septal defects. Individuals are also at increased risk for early-onset Alzheimer disease, leukemia, and thyroid dysfunction. Diagnosis is important for early intervention and management of associated complications.
Inciting Event
Meiotic nondisjunction during gametogenesis leads to trisomy of chromosome 21.
Less commonly, Robertsonian translocation or mosaicism causes Down syndrome.
No environmental or infectious triggers are implicated in the chromosomal abnormality.
The error typically occurs in maternal meiosis I.
Paternal nondisjunction is rare but possible.
Latency Period
Symptoms and physical features are present at birth or become apparent in the neonatal period.
Developmental delays and intellectual disability become evident in infancy to early childhood.
Congenital heart defects are diagnosed in the neonatal period.
Autoimmune and hematologic complications may develop later in childhood or adolescence.
Alzheimer disease pathology manifests in middle age.
Diagnostic Delay
Mild phenotypes or mosaicism can lead to delayed recognition of Down syndrome.
Lack of prenatal screening or limited access to karyotyping delays diagnosis.
Overlap of features with other syndromes may cause initial misattribution.
Subtle intellectual disability may be mistaken for other developmental disorders.
Newborns without obvious dysmorphic features may be missed initially.
Clinical Presentation
Signs & Symptoms
Developmental delay with intellectual disability
Hypotonia causing poor muscle tone and delayed milestones
Feeding difficulties in infancy
Congenital heart defects presenting with murmur or heart failure signs
Frequent respiratory infections due to immune dysfunction
Short stature and characteristic facial features
History of Present Illness
Parents report hypotonia and feeding difficulties in the neonatal period.
Developmental milestones are delayed, including motor and speech delays.
Characteristic facial features such as upslanting palpebral fissures and flat nasal bridge are noted.
Frequent respiratory infections due to immune dysfunction are common.
Congenital heart disease symptoms like cyanosis or heart murmur may be present early.
Past Medical History
History of congenital heart defects such as atrioventricular septal defect or ventricular septal defect.
Previous episodes of otitis media or respiratory infections due to immune compromise.
Documented hypothyroidism or other endocrine abnormalities.
Prior developmental assessments showing intellectual disability or global developmental delay.
No specific medication exposures cause Down syndrome but supportive therapies are common.
Family History
Family history of Down syndrome or chromosomal abnormalities increases risk.
Parental balanced Robertsonian translocation involving chromosome 21 may be present.
No typical inheritance pattern as most cases are due to de novo nondisjunction.
Siblings may be unaffected or have variable phenotypes in mosaic cases.
Genetic counseling is recommended for families with history of chromosomal rearrangements.
Physical Exam Findings
Upward slanting palpebral fissures with epicanthal folds
Single transverse palmar crease (simian crease)
Hypotonia with decreased muscle tone
Brachycephaly with flat occiput
Protruding tongue due to small oral cavity
Brushfield spots (white spots on the iris)
Diagnostic Workup
Diagnostic Criteria
Diagnosis is established by karyotype analysis demonstrating trisomy of chromosome 21. Prenatal screening includes maternal serum markers and ultrasound findings such as increased nuchal translucency. Definitive diagnosis requires chromosomal analysis from peripheral blood showing three copies of chromosome 21. Characteristic clinical features support the diagnosis but must be confirmed cytogenetically. Molecular techniques like fluorescence in situ hybridization (FISH) can provide rapid confirmation.
Pathophysiology
Key Mechanisms
Presence of an extra copy of chromosome 21 causes gene dosage imbalance leading to multisystem developmental abnormalities.
Trisomy 21 disrupts normal cellular processes including neuronal development and immune function.
Overexpression of genes on chromosome 21, such as APP, contributes to early-onset Alzheimer disease pathology.
Abnormalities in craniofacial development result from altered signaling pathways influenced by trisomy 21.
Impaired immune regulation increases susceptibility to infections and autoimmune disorders.
| Involvement | Details |
|---|---|
| Organs | Heart is commonly affected by congenital malformations requiring early diagnosis and management. |
Thyroid gland dysfunction is prevalent and necessitates regular screening and treatment. | |
Brain demonstrates characteristic developmental abnormalities underlying intellectual disability and early neurodegeneration. | |
| Tissues | Brain tissue shows reduced volume and abnormal neuronal connectivity causing cognitive impairment. |
Cardiac tissue frequently exhibits structural defects like atrioventricular septal defects impacting cardiovascular function. | |
Thyroid tissue is prone to autoimmune thyroiditis leading to hypothyroidism. | |
| Cells | Lymphocytes show altered immune function contributing to increased susceptibility to infections in Down syndrome. |
Neurons exhibit abnormal development and reduced numbers leading to intellectual disability and early-onset Alzheimer disease. | |
Osteoblasts have impaired function contributing to low bone density and increased fracture risk. | |
| Chemical Mediators | Superoxide dismutase 1 (SOD1) is overexpressed due to trisomy 21, increasing oxidative stress and cellular damage. |
Amyloid precursor protein (APP) overexpression leads to early amyloid plaque formation and Alzheimer disease pathology. | |
Cytokines such as interleukin-6 are elevated, contributing to chronic inflammation and immune dysregulation. |
Treatments
Pharmacological Treatments
Non-pharmacological Treatments
Early intervention programs with physical, occupational, and speech therapy improve developmental outcomes in Down syndrome.
Regular cardiac evaluations and surgical correction of congenital heart defects reduce morbidity and mortality.
Routine thyroid function monitoring and hormone replacement therapy manage hypothyroidism common in Down syndrome.
Special education and behavioral therapy support cognitive development and social skills.
Nutritional support and management of feeding difficulties optimize growth and health.
Prevention
Pharmacological Prevention
Thyroid hormone replacement to prevent hypothyroidism complications
Prophylactic antibiotics are not routinely recommended but may be used for recurrent infections
No pharmacological agents prevent trisomy 21 itself
Non-pharmacological Prevention
Prenatal screening with cell-free fetal DNA and ultrasound for early detection
Genetic counseling for families with history of chromosomal abnormalities
Early intervention programs to improve developmental outcomes
Regular cardiac and thyroid screening to detect and manage comorbidities early
Avoidance of high-risk activities in patients with atlantoaxial instability
Outcome & Complications
Complications
Atlantoaxial instability leading to spinal cord compression
Pulmonary hypertension secondary to congenital heart defects
Increased risk of infections due to immune dysregulation
Early-onset Alzheimer disease in adulthood
Thyroid dysfunction causing metabolic complications
Obstructive sleep apnea causing cardiovascular strain
| Short-term Sequelae | Long-term Sequelae |
|---|---|
|
|
Differential Diagnoses
Down Syndrome (Trisomy 21) versus Edwards Syndrome (Trisomy 18)
Down Syndrome (Trisomy 21) | Edwards Syndrome (Trisomy 18) |
|---|---|
Presence of trisomy 21 on karyotype | Presence of trisomy 18 on karyotype |
Survival into childhood with characteristic developmental delay | Severe congenital anomalies with high neonatal mortality |
Nuchal translucency and duodenal atresia on prenatal ultrasound | Clenched fists with overlapping fingers on prenatal ultrasound |
Down Syndrome (Trisomy 21) versus Patau Syndrome (Trisomy 13)
Down Syndrome (Trisomy 21) | Patau Syndrome (Trisomy 13) |
|---|---|
Presence of trisomy 21 on karyotype | Presence of trisomy 13 on karyotype |
Characteristic facial features and intellectual disability with longer survival | Severe midline defects with most infants dying within the first month |
Normal brain structure or mild abnormalities on brain imaging | Holoprosencephaly on brain imaging |
Down Syndrome (Trisomy 21) versus Fragile X Syndrome
Down Syndrome (Trisomy 21) | Fragile X Syndrome |
|---|---|
Trisomy 21 (chromosomal nondisjunction) with no sex linkage | X-linked dominant inheritance with CGG repeat expansion in FMR1 gene |
Extra chromosome 21 on karyotype | FMR1 gene methylation and CGG repeat expansion on genetic testing |
Static intellectual disability with characteristic physical features | Progressive intellectual disability with behavioral features like autism and hyperactivity |
Down Syndrome (Trisomy 21) versus Williams Syndrome
Down Syndrome (Trisomy 21) | Williams Syndrome |
|---|---|
Trisomy 21 detected by karyotype | Microdeletion at 7q11.23 detected by FISH |
Flat facial profile, intellectual disability, and atrioventricular septal defects | Elfin facies, supravalvular aortic stenosis, and strong verbal skills |
Moderate to severe intellectual disability with typical developmental delays | Mild to moderate intellectual disability with unique personality traits |
Down Syndrome (Trisomy 21) versus Noonan Syndrome
Down Syndrome (Trisomy 21) | Noonan Syndrome |
|---|---|
Chromosomal trisomy 21 with nondisjunction | Autosomal dominant mutations in genes affecting the RAS/MAPK pathway |
Atrioventricular septal defects, hypotonia, and characteristic facial features | Pulmonary valve stenosis, short stature, and webbed neck |
Karyotype showing trisomy 21 | Molecular genetic testing showing mutations in PTPN11, SOS1, or related genes |